Jeffrey Del - Mar 29, 2023 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Commercial Officer
Signature
/s/ Jeffrey Del Carmen
Stock symbol
CPRX
Transactions as of
Mar 29, 2023
Transactions value $
-$540,746
Form type
4
Date filed
3/30/2023, 05:01 PM
Previous filing
Feb 17, 2023
Next filing
Jun 29, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $47K +21K +278.25% $2.24* 28.5K Mar 29, 2023 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$350K -21K -73.56% $16.70 7.54K Mar 29, 2023 Direct F1, F2
transaction CPRX Common stock, par value $0.001 per share Options Exercise $80.1K +19K +252.18% $4.21 26.6K Mar 29, 2023 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$317K -19K -71.61% $16.69 7.54K Mar 29, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -21K -2.95% $0.00 690K Mar 29, 2023 Common Stock 21K $2.24 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -19K -2.75% $0.00 671K Mar 29, 2023 Common Stock 19K $4.21 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold to cover exercise price of options, tax withholding requirements and for personal reasons. Shares were not sold as a result of any disagreement with the Company. Mr. Del Carmen remains an officer of the Company.
F2 Shares were sold in various lots from $16.65 to $16.735 per share. The price listed represents a weighted average price for the shares sold.
F3 Shares were sold in various lots from $16.645 to $16.74 per share. The price listed represents a weighted average price for the shares sold.
F4 Options vested in three annual tranches beginning on December 19, 2019.
F5 Options vested in three annual tranches beginning on January 6, 2021.